Literature DB >> 33426053

lncRNA RHPN1-AS1 Serves as a Sponge for miR-3133 Modulating the Cell Proliferation of Retinoblastoma through JAK2.

Zhao-Na Li1, Ming-Xu Ge2, Li-Jun Cao1, Zhong-Fang Yuan3.   

Abstract

PURPOSE: To investigate the effects of lncRNA RHPN1-AS1 on retinoblastoma (RB) and further explore its underlying molecular mechanisms.
METHODS: The expression of RHPN1-AS1, miR-3133, (JAK2), and signal transducer and activator of transcription 3 (STAT3) was detected by qRT-PCR. CCK-8, EDU, and flow cytometry assays were conducted to assess the proliferation activity and apoptosis of RB cells. Double fluorescein and RNA immunoprecipitation assays were performed to detect the interaction between RHPN1-AS1 and miR-3133 or miR-3133 and JAK2. Western blotting was performed to detect the expression of apoptosis-related proteins.
RESULTS: In RB cells, RHPN1-AS1 was upregulated. Silencing RHPN1-AS1 inhibited the activity of RB cells and promoted apoptosis. The expressions of proapoptotic factors (Bax and p53) were increased, while antiapoptotic factors (Bcl-2 and Survivin) were suppressed in siRHPN1-AS1 groups. Furthermore, we predicted and verified that RHPN1-AS1 regulated RB progression by targeting miR-3133/JAK2. In addition, siRHPN1-AS1 also inhibited oncogene STAT3 protein expression.
CONCLUSION: lncRNA RHPN1-AS1 served as a sponge for miR-3133 to counteract miR-3133-mediated JAK2/STAT3 suppression, indicating that the lncRNA RHPN1-AS1 may be a potential therapeutic target for the treatment of RB.
Copyright © 2020 Zhao-Na Li et al.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33426053      PMCID: PMC7773464          DOI: 10.1155/2020/3502981

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


  29 in total

Review 1.  Towards a complete map of the human long non-coding RNA transcriptome.

Authors:  Barbara Uszczynska-Ratajczak; Julien Lagarde; Adam Frankish; Roderic Guigó; Rory Johnson
Journal:  Nat Rev Genet       Date:  2018-09       Impact factor: 53.242

2.  The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death.

Authors:  Tero Kivelä
Journal:  Br J Ophthalmol       Date:  2009-09       Impact factor: 4.638

3.  c-Myc induced the regulation of long non-coding RNA RHPN1-AS1 on breast cancer cell proliferation via inhibiting P53.

Authors:  Pei Zhu; Yan Li; Ping Li; Yuying Zhang; Xiaowei Wang
Journal:  Mol Genet Genomics       Date:  2019-05-14       Impact factor: 3.291

Review 4.  Therapeutic Options for Retinoblastoma.

Authors:  Pia R Mendoza; Hans E Grossniklaus
Journal:  Cancer Control       Date:  2016-04       Impact factor: 3.302

Review 5.  Non-coding RNA networks in cancer.

Authors:  Eleni Anastasiadou; Leni S Jacob; Frank J Slack
Journal:  Nat Rev Cancer       Date:  2017-11-24       Impact factor: 60.716

Review 6.  Targeting noncoding RNAs in disease.

Authors:  Brian D Adams; Christine Parsons; Lisa Walker; Wen Cai Zhang; Frank J Slack
Journal:  J Clin Invest       Date:  2017-03-01       Impact factor: 14.808

7.  LncRNA RHPN1-AS1 promoted cell proliferation, invasion and migration in cervical cancer via the modulation of miR-299-3p/FGF2 axis.

Authors:  Haixia Duan; Xiaojuan Li; Youyi Chen; Yan Wang; Zhibin Li
Journal:  Life Sci       Date:  2019-09-13       Impact factor: 5.037

8.  The Long Non-Coding RNA RHPN1-AS1 Promotes Uveal Melanoma Progression.

Authors:  Linna Lu; Xiaoyu Yu; Leilei Zhang; Xia Ding; Hui Pan; Xuyang Wen; Shiqiong Xu; Yue Xing; Jiayan Fan; Shengfang Ge; He Zhang; Renbing Jia; Xianqun Fan
Journal:  Int J Mol Sci       Date:  2017-01-23       Impact factor: 5.923

Review 9.  Dysregulated expression of long noncoding RNAs in gynecologic cancers.

Authors:  Elahe Seyed Hosseini; Matthieu Meryet-Figuiere; Hamed Sabzalipoor; Hamed Haddad Kashani; Hossein Nikzad; Zatollah Asemi
Journal:  Mol Cancer       Date:  2017-06-21       Impact factor: 27.401

10.  Expression of microRNA-3133 correlates with the prognosis in patients with clear cell renal cell carcinoma.

Authors:  Xiaoyan Chen
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.